Fludarabine

製品コードS1491 別名:FaraA, Fludarabinum

Fludarabine化学構造

分子量(MW):285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.

サイズ 価格(税別)  
JPY 20932.00
JPY 16102.00
JPY 51460.00
JPY 78020.00

カスタマーフィードバック(5)

  • Br J Cancer, 2018, 118(4):509-521. Fludarabine purchased from Selleck.

    ERK signaling regulates STAT1 phosphorylation, and pSTAT1 modulates MHC II expression in the spinal cord under BCP conditions. AG490 (5 μg in 10 μL), Fludarabine (10 μg in 10 μL), or U0126 (5 μg in 10 μL) was intrathecally injected into cancer-bearing rats once a day for 14 days, beginning immediately after carcinoma cell inoculation (n = 3 in each group). (A) Representative western blot showing pSTAT1ser727, total STAT1, pERK42/44, total ERK42/44, CIITA, MHC II RTIB, and b actin protein levels in the spinal cords of BCP rats.

    Brain Behav Immun, 2017, 60:161-173. Fludarabine purchased from Selleck.

  • Imatinib mesylate (IM) in combination of fludarabine phosphate (F-AMP) significantly inhibits Ki67 and c-KIT expression in GIST-T1 tumor xenografts. Tumors were collected on the day after the last treatment and were then subjected to immunohistochemical detection of Ki67 and c-KIT expression. Representative images of immunohistochemical staining of Ki67 and c-KIT in mice tumors.

    Mol Cancer Ther, 2014, 13(10): 2276-87 . Fludarabine purchased from Selleck.

    Normal human KC pretreated with STAT1 inhibitor (fludarabine [10 uM]) or STAT3 inhibitor (STA-21 [2 uM]) for 24 h. The mRNA levels of hBD2 and hBD3 were assessed by qRT-PCR.

    Mol Cell Biol 2014 34(24), 4368-78.. Fludarabine purchased from Selleck.

  • Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 10 μM fludarabine. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.

    Int Immunopharmacol, 2016, 36:199-204.. Fludarabine purchased from Selleck.

製品安全説明書

STAT阻害剤の選択性比較

生物活性

製品説明 Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells.
ターゲット
STAT1 [4]
(Vascular smooth muscle cells)
体外試験

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  NUK1U|VWTnWwY4Tpc44hSXO|YYm= Mme4NlAh|ryP MWKyOEBp NYWwPGg{cW6qaXLpeJMh\XiycnXzd4lwdiCxZjDJSG8> MX:yOVk1ODdzMh?=
MV-4-11 M2P1TWFxd3C2b4Ppd{BCe3OjeR?= MYWyMlUh|ryP NYn2eZBTPDhiaB?= MnLDbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MlrNNlUyOTF3OEO=
THP-1 M3zlV2Fxd3C2b4Ppd{BCe3OjeR?= NIrRXnMzNjVizszN NEDaT5I1QCCq MVrpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= Mn3lNlUyOTF3OEO=
MOLM 13 NIrpcoJCeG:ydH;zbZMhSXO|YYm= NFXsRWYzNjVizszN MlrsOFghcA>? MWnpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NEjzTnkzPTFzMUW4Ny=>
KBM3/Bu2506 MYXBdI9xfG:|aYOgRZN{[Xl? NYTIVGVPOi53IN88US=> NWXQWJl2PDhiaB?= NXLxbId4cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MVOyOVEyOTV6Mx?=
Nalm-6 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK1fYFKSzVyPUG4JO69VQ>? MXSyOVA3OTFyMR?=
Reh MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNyIN88US=> MkC1NlUxPjFzMEG=
U2937 M2TibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS2XW9KSzVyPUG2JO69VQ>? MW[yOVA3OTFyMR?=
Mec-1 NXT0VW5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|Ux97zgNUCwJO69VQ>? MkDqNlUxPjFzMEG=
RPMI-8226 Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G4ZmlEPTB;NUCwJO69VQ>? NIqxZ5MzPTB4MUGwNS=>
Molt-4 MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHzWFJKSzVyPUG4NEDPxE1? M4TpRlI2ODZzMUCx
Nalm-6-FluR M3TmTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLHTWM2OD1{NUCg{txO NU\wcGFNOjVyNkGxNFE>
Raji  MnqzSpVv[3Srb36gRZN{[Xl? NWrB[4NuO8LizszN NIL1PYQzPC92OD:3NkBp NWLYb4FXcW6mdXPld{Bi[2O3bYXsZZRqd26|IH;mJJA2OyxicE[zJIFv\CCyN{RCpC=> NF\COFQzPDl2ME[5OS=>
PBMC NX[1eYZQTnWwY4Tpc44hSXO|YYm= Mn7rOVAwOTByIN88US=> NU\xXlFbOjRiaB?= NIL4SYJFVVOR M2LC[olvcGmkaYTzJHNVSVRzIIDoc5NxcG:{eXzheIlwdg>? MnjkNlQ6OTF6N{K=
MDA-231 NYHxNVZDTnWwY4Tpc44hSXO|YYm= NGDCUWUyODBizszN MX:yOEBp NXnjbIJuTE2VTx?= MlPO[IVkemWjc3XzJGlFVyCneIDy[ZN{cW:w NH\DT4EzPDlzMUi3Ni=>
624.38mel  NI\BTFNHfW6ldHnvckBCe3OjeR?= NGXlOpg2OCEQvF2= MYKyOEBp MnnYSG1UVw>? M{XWToRm[3KnYYPld{BKTE9iZYjwdoV{e2mxbh?= NHjvPHUzPDlzMUi3Ni=>
MDA-231 Mmq5SpVv[3Srb36gRZN{[Xl? M4i0ZVUxNTJyMDFOwG0> NE[0[VQzPCCq NGfBV|BFVVOR MV;pcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>? MorCNlQ6OTF6N{K=
624.38mel  NYPYVnp2TnWwY4Tpc44hSXO|YYm= MnPYOVAuOjByIN88US=> MXWyOEBp MWTEUXNQ MnjsbY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN? M1G2XVI1QTFzOEey
HMECs MnrOSpVv[3Srb36gRZN{[Xl? NF3xT3cyODEEoN88UeKh NVHKNHFTOzcEoHi= MWfpcohq[mm2czDJSm7Pu8LiYX7kJGxRWyCrbnT1Z4VlKFOWQWSxJJBpd3OyaH;yfYxifGmxbjDhcoQhUVKIMTDlfJBz\XO|aX;u M1vS[lI1OjFzM{K3
HMECs  NIT0U3ZHfW6ldHnvckBCe3OjeR?= MmjyNVAxyqEQvF5CpC=> MWqzOuKhcA>? M1nQZolvcGmkaYTzJGlHVs7zwrDt[YRq[XSnZDDwbI9{eGixconsZZRqd25ib3[gV3RCXDFiYX7kJHNVSVR|LDDieZQhdm:2IH;mJHNVSVR{ NYDWfZRuOjR{MUGzNlc>
BJAB MlH4RZBweHSxc3nzJGF{e2G7 NX;w[oZXPcLizszN NGjWNmwzPCCq NVG4NIoxcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NGDIc4YzPDB3N{G0Oy=>
I-83 M3XKTGFxd3C2b4Ppd{BCe3OjeR?= MVW1xsDPxE1? M2TlWFI1KGh? MVnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MojVNlQxPTdzNEe=
NALM6 M4PhNmFxd3C2b4Ppd{BCe3OjeR?= MXG1xsDPxE1? NX;1OVNlOjRiaB?= NWn2ZYZPcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWL4[45oOjRyNUexOFc>
DU-145 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInoWIExNTFyIN88[{9udA>? MWq0PEBpyqB? NGXlbotqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX;xdGVUOjN5M{S4NVU>
Nalm-6 NFLaSmdHfW6ldHnvckBCe3OjeR?= M3T6bFExyqEQvF2= MmPKNU8zNzRiaB?= MWHpcoR2[2W|IHH1eI9xcGGpeR?= MmnSNlM3QDF{MkO=
Reh MnS3SpVv[3Srb36gRZN{[Xl? MlrONVDDqM7:TR?= M3G5[FEwOi92IHi= M1jqbolv\HWlZYOgZZV1d3CqYXf5 NEnXb|YzOzZ6MUKyNy=>
Nalm-6 NH\jRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfBWGZKSzVyIPMIwFEx6oDLzszN Ml7LNlM3QDF{MkO=
Reh M3zMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG4S5NqUUN3MDFijNwyOOLCid88US=> MX[yN|Y5OTJ{Mx?=
HEC1A MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zU[VExOC13MECg{txO MmPjNlQhcA>? NFLpZnRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIT0cGYzOzV7NU[5Oy=>
AN3CA MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrkNVAxNTVyMDFOwG0> NUXqWJFWOjRiaB?= MnjRbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXmyN|U6PTZ7Nx?=
HEC50B M4rSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXsNVAxNTVyMDFOwG0> NUjWeZRxOjRiaB?= NFvncmJqdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? MVuyN|U6PTZ7Nx?=
HEC1A NICwTlNCeG:ydH;zbZMhSXO|YYm= MVuyNE8yODBizszN MlPyNlQhcA>? M2nWZYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MX2yN|U6PTZ7Nx?=
AN3CA NIXs[pZCeG:ydH;zbZMhSXO|YYm= MmH6NlAwOTByIN88US=> MoTkNlQhcA>? NHT1eXNqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHr6doozOzV7NU[5Oy=>
HEC50B M2D4cGFxd3C2b4Ppd{BCe3OjeR?= MmC4NlAwOTByIN88US=> NWHXUWlpOjRiaB?= MWDpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= Mo\2NlM2QTV4OUe=
EHEB NFrtb5NCeG:ydH;zbZMhSXO|YYm= NHTV[oQ1OCEQvF2= M{iwZlI1KGh? MWPpcoR2[2W|IHHwc5B1d3Orcx?= M1jRelI{PDl5MEe1
A549 NInKN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\vVHYzUUN3ME2xOU44yrF{LkigxtVO MYmyN|M4PzF7Mh?=
A549 GAPDH-deficient NXP0TYJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LROWlEPTB;MUiuOeKyOi5|INM1US=> MXOyN|M4PzF7Mh?=
CLL  NVPCeYVoSXCxcITvd4l{KEG|c3H5 MXexNEDPxE4EoB?= NXH2U3pxOjRvOU[gbC=> MoLjbY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> MnvQNlIzODd4OE[=
MEC1 MlO2RZBweHSxc3nzJGF{e2G7 NIn1WosyODEEoN88US=> Mlv2O|IhcA>? MnWxbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NYXBeGZMOjJzM{K5O|M>
U937  MmXQRZBweHSxc3nzJGF{e2G7 M2\FOVAvQCEQvF2= NF;IbGk1NTR6IHi= Ml7IbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= M2rWO|IzODd2N{Cw
U937  M3LsOWFxd3C2b4Ppd{BCe3OjeR?= M2fKRVEh|ryP NVrlbYVkQTZiaB?= NGPqdWxqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> MUeyNlAzOzV{Mx?=
Daudi MVLBdI9xfG:|aYOgRZN{[Xl? Ml\VNlAh|ryP MV[5OkBp MVvpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= M1;UZVIzODJ|NUKz
J45.01 M2fjZWFxd3C2b4Ppd{BCe3OjeR?= MnjJNUDPxE1? NUTWd25JQTZiaB?= MnzUbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MXuyNlAzOzV{Mx?=
RPMI 8226 NU\ZSVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDIOFlKSzVyPUK1MlnDqMLzwrCzMlch|ryP MlziNlE6PDh{NkS=
CEM NGDsbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHmTWM2OD1{LkVCpOKyyqByLkSg{txO M3fPfVIyQTR6Mk[0
Raji Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNEhCpOKyyqByLkC0JO69VQ>? NHe1fIQzOTl2OEK2OC=>
U937 NVfpe5JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDuVYFMUUN3ME2wMlI1yqEEsdMgNE4xPCEQvF2= M{TlOlIyQTR6Mk[0
K562 M1zqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK4V3hKSzVyPUCuOFTDqMLzwrCwMlA2KM7:TR?= M3XoV|IyQTR6Mk[0
NALM-6 M3TLc2Fxd3C2b4Ppd{BCe3OjeR?= NWHBd5g2OTBizszNxsA> M4HtOVI1KGh? MlPQbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|bHnnbJRtgQ>? NUDuc3pIOjF4OUmzPFM>
JMV-3 MoG5RZBweHSxc3nzJGF{e2G7 MXSxNEDPxE4EoB?= NWqy[ndTOjRiaB?= M4KwN4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl? MkDkNlE3QTl|OEO=
EHEB NUjITmR{TnWwY4Tpc44hSXO|YYm= MoKzOU02OCEQvF2= NVmwRnZZOjRiaB?= MX7k[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> NU\BU443OjFzNkizPVE>
JVM-2  MYDGeY5kfGmxbjDBd5NigQ>? NYLWe5d1OzBizszN MUGyOEBp MkTj[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:w M333[VIyOTZ6M{mx
KBM3/Bu2506 NFjDR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELPbJBKSzJyPUCuOlchyrWP MkPuNlA6OzN3MEm=
KBM3/Bu2506 Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXhN5AxNjZizszN NIXPRoMzPCCq Mli4bY5kemWjc3XzJJRp\SClZXzsJIZz[WO2aX;uJIlvKFNvcHjhd4U> NYmyWYMzOjB7M{O1NFk>
MDA-MB-231 NETFN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7Q[m5yUUN3ME20MlAh|ryP MWqyNFQ1PzN7MB?=
MCF-7 NIjUSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvHbXlZUUN3ME2xOU4xKM7:TR?= MVmyNFQ1PzN7MB?=
HLE-B3  MmjMSpVv[3Srb36gRZN{[Xl? NIewNnMzPSEQvF2= MmX5OFghcA>? NU\ofWNb[myxY3vzJGlHVi4Qs,MAl4lv\HWlZXSgV3RCXDFicHjvd5Bpd3K7bHH0bY9vKGGwZDDJSG8h\XiycnXzd4lwdg>? NWHjN5JMOjB2M{WxOVg>
K562 M4ixVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe3NkBp NYGwfpNUUUN3ME2zMlMhdk1? M3i3OVIxOzB5MUm4
BW-225 NFPZdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHNW5FyUUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=> NHi3OooyQDZ4MUO4NC=>
OH-65 NHTvO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPBSIZKSzJyPUGuN|chy5dzMPMIlljDqM7:TdMg NE\aR4MyQDZ4MUO4NC=>
GR-145 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4n4XmlEOjB;Mj63OEDEnyBzMPMIllghKM7:TdMg MkDyNVg3PjF|OEC=
A549 MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnNTWMzOD13LkS4JOOYKDFy4pkSPEDPxE4EoB?= MYOxPFY3OTN6MB?=
CaSki  NVHtWmp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvqXpdQUUN{ME2xMlM4KMPZIEGw5qiTPyEQvF5CpC=> NYO4THlwOTh4NkGzPFA>
ZMK-1 M2fzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|IxRTFwM{egx7chOTEkiKK2JO69VcLi MYexPFY3OTN6MB?=
SKW6.4 M{nnWWFxd3C2b4Ppd{BCe3OjeR?= MkDONE4xOS1zMDFOwG0> NGO0bHEzPC92ODDo NWPBbXpNcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= MmHzNVgxQTJ|NEC=
RPMI 8226 NV7RU2R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LtbFI1KGh? NVTiZmo6UUN3ME2xMlU1yqEQvF2= NIDsWW8yPzl5NkG4Oi=>
MM.1S MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP3OFghcA>? MoLlTWM2OD1zMz60POKh|ryP NFfrUYcyPzl5NkG4Oi=>
MM.1R NIf0WZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn2bGs1QCCq MVzJR|UxRTN|Lke5JO69VQ>? NVnBT2Q4OTd7N{[xPFY>
U937 NV\2O2o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGzbnpKSzVyPUOsNlAxKMLzIEW2NEBvVQ>? NEfFfWcyPTl|MEO2NS=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • 濃度: 2 μg/mL
  • 反応時間: 24 hours
  • 実験の流れ:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • 製剤: PBS
  • 投薬量: 40 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% propylene glycol, 5% Tween 80, 65% D5W
混合させたのち直ちに使用することを推奨します。
30 mg/mL (suspension)

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 285.23
化学式

C10H12FN5O4

CAS No. 21679-14-1
保管
in solvent
別名 FaraA, Fludarabinum

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03579888 Not yet recruiting Acute Lymphoblastic Leukemia|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|CD19 Positive|Chronic Lymphocytic Leukemia|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma M.D. Anderson Cancer Center|Ziopharm Oncology|Precigen Inc December 2019 Phase 1
NCT03579888 Not yet recruiting Acute Lymphoblastic Leukemia|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|CD19 Positive|Chronic Lymphocytic Leukemia|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma M.D. Anderson Cancer Center|Ziopharm Oncology|Precigen Inc December 2019 Phase 1
NCT03873805 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 City of Hope Medical Center|National Cancer Institute (NCI) August 1 2019 Phase 1
NCT03873805 Not yet recruiting Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8 City of Hope Medical Center|National Cancer Institute (NCI) August 1 2019 Phase 1
NCT03710421 Not yet recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma City of Hope Medical Center|National Cancer Institute (NCI) June 10 2019 Phase 1
NCT03856216 Not yet recruiting Acute Lymphoblastic Leukemia|Allogeneic Hematopoietic Stem Cell Transplantation Recipient|B Acute Lymphoblastic Leukemia|CD22 Positive|Lymphocytic Neoplasm|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) June 30 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • 回答:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STATシグナル伝達経路

相関STAT製品

Tags: Fludarabineを買う | Fludarabine ic50 | Fludarabine供給者 | Fludarabineを購入する | Fludarabine費用 | Fludarabine生産者 | オーダーFludarabine | Fludarabine化学構造 | Fludarabine分子量 | Fludarabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID